LDDD
Longduoduo Company Limited0.5933
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
17.81MP/E (TTM)
59.33Basic EPS (TTM)
0.01Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Longduoduo's Q2 FY2026 revenue plunged 81% y/y to $345K from $1.8M, driven by commission drop amid China's cautious consumer spending, while service revenue ticked to $4K; gross profit held at 98.5% thanks to near-zero service costs. Operating loss hit $279K versus $603K profit last year, as SG&A fell 46% to $619K on lower advertising, yet still outpaced topline. Cash dipped to $1.5M after $106K ops outflow, with $30K capex; no debt, $634K working capital. One customer drove 99% revenue. Customer concentration bites hard.
10-Q
Q1 FY2026 results
Longduoduo's Q1 FY2026 revenue dipped 14% y/y to $658.8K, driven by commission revenue falling to $653.2K while service revenue shrank sharply to $5.6K; gross profit held at 99% but operating loss widened 36% y/y to $84.4K on steady SG&A. Net loss hit $111.2K, versus $59.5K last year, as taxes jumped to $67.1K while other income rose to $40.3K. Cash burned $374K in operations, ending at $1.2M with no debt. One customer drove 99.1% of revenue. Customer concentration bites hard.
10-K
FY2025 results
Longduoduo's FY2025 revenue fell 42% y/y to $4.3M, with commissions from Honghai at 97% driving the drop from post-pandemic surge while service sales plunged 63% y/y to $121K at 25% gross margin. Operating income shrank 73% to $553K as ad spend halved to $1.9M amid economic headwinds in Inner Mongolia, yet net income held at $492K ($0.015/share). Cash swelled to $1.6M with $277K operating inflow; no debt or buybacks. Q4 momentum not disclosed. PRC rules could block dividends to U.S. parent.
10-Q
Q3 FY2025 results
Longduoduo's Q3 revenue fell 57% y/y to $778K (derived), with commission revenue dominating at $749K amid post-pandemic normalization and softer health spending, yet gross profit held at 97% while operating expenses dropped 15% y/y to $876K (derived), swinging to a $119K operating loss. YTD through March 31, 2025, revenue declined 42% y/y to $3.3M but operating income stayed positive at $422K, delivering $0.010 diluted EPS on 30M shares—consistent with net income to common of $297K. Cash grew to $1.5M on $93K operating cash flow, free cash flow $64K after $29K capex (derived); no debt, lean liabilities. Issued 10K shares for LDD acquisition Feb 2025 (stock). Customer concentration persists.
8-K
Equity transfer restructures ops
Longduoduo subsidiaries shuffled equity on April 2, 2025, transferring 100% of Longduoduo Health Technology Co. (RMB 99.99 million registered capital) from Hong Kong entity to Beijing Julong for RMB 4 million. HTC and its four subsidiaries had run all registrant operations until January 2025. Now business flows through seven China units under new structure. Transfer complete that day.
IPO
Website
Employees
Sector
Industry
BNR
Burning Rock Biotech Limited
18.74+2.98
CHEK
Check-Cap Ltd.
1.61+0.03
CODX
Co-Diagnostics, Inc.
0.25-0.02
CORBF
Global Cord Blood Corporation
0.80-0.15
DGX
Quest Diagnostics Incorporated
178.66-5.45
LH
Labcorp Holdings Inc.
258.11-5.22
MEHCQ
CHROME HLDG CO
3.50+0.00
PRE
Prenetics Global Limited
16.58+1.95
WGS
GeneDx Holdings Corp.
141.72-8.89
YDES
YD Bio Limited
12.62+0.22